The Diagnostic Value of APTT/Fibrinogen Ratio in Pulmonary Embolism
Key facts
- Who runs it
- Nanfang Hospital, Southern Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 1,000 people enrolled
- Started
- 1 Jan 2018
- Ended
- 1 Dec 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- 2018 edition of the Guidelines for Diagnosis
- Record updated
- 1 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- Voluntary signing of informed consent form
- When signing the informed consent form, the age is equal to or greater than 18 years old, regardless of gender
- From January 1, 2023 to December 30, 2023, the patient was diagnosed with suspected pulmonary embolism at the Southern Hospital of Southern Medical University and underwent enhanced pulmonary artery scanning examination
Who cannot take part
- Patients undergoing regular anticoagulant therapy such as atrial fibrillation and valve replacement
- Patients with gastrointestinal bleeding, severe trauma, acute coronary syndrome, severe liver disease (childC grade), and coagulation dysfunction
- Patients with pulmonary embolism diagnosed outside the hospital and regular anticoagulation
- Patients deemed unsuitable for participation in this study by the researchers
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
From January 1, 2023 to December 30, 2023, patients who were suspected of pulmonary embolism and underwent CTPA examination at Nanyang Hospital of Southern Medical University were divided into pulmonary embolism group and non pulmonary embolism group. 1. Collect relevant data, including gender, age, primary disease, CTPA imaging and reports, BNP, troponin, electrocardiogram, cardiac ultrasound, PT, APTT, TT, fibrinogen, D-dimer, etc., and analyze demographic data, pulmonary embolism risk grading, APTT/fibrinogen ratio, and determine their cut-off values through statistical analysis of the two groups. 2. Follow up on the APTT/fibrinogen ratio after anticoagulation treatment and bleeding in the pulmonary embolism group.
The 2 groups in the trial
- Patients with acute pulmonary embolism
Treatment: 2018 edition of the Guidelines for Diagnosis
- Patients without acute pulmonary embolism
Treatment: 2018 edition of the Guidelines for Diagnosis
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 1 July 2026